Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium

Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium

Biopharmaceuticals (BPs) represent a rapidly growing class of approved and investigational drug therapies that is contributing significantly to advancing treatment in multiple disease areas, including inflammatory and autoimmune diseases, genetic deficiencies and cancer. Unfortunately, unwanted immu...

Full description

Bibliographic Details
Main Authors: Rup, B, Pallardy, M, Sikkema, D, Albert, T, Allez, M, Broet, P, Carini, C, Creeke, P, Davidson, J, De Vries, N, Finco, D, Fogdell-Hahn, A, Havrdova, E, Hincelin-Mery, A, C Holland, M, H Jensen, P E, Jury, E C, Kirby, H, Kramer, D, Lacroix-Desmazes, S, Legrand, J, Maggi, E, Maillère, B, Mariette, X, Mauri, C, Mikol, V, Mulleman, D, Oldenburg, J, Paintaud, G, R Pedersen, C, Ruperto, N, Seitz, R, Spindeldreher, S, Deisenhammer, F
Format: Online
Language:English
Published: John Wiley & Sons, Ltd 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4557374/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4557374/

Similar Items